Onslow Memorial partners with Daisy Foundation recognize nurses and support staff
This is the first year they will be giving away Daisy and Petals Awards. The Daisy Foundation is a national nonprofit created to thank nurses for making a difference in patients' lives.
New or old patients, family members and staff can nominate someone on the hospital's website. Daisy Awards are specifically for nurses while Petals are for other teammates that help with care. Winners will get a certificate, a daisy award pin and a healers touch sculpture.
'It's important to have this Daisy Award recognition program here because we do want to highlight our nurses. We want to make sure that they know that we see them in our patients, see them because they do so much for our patients, they do so much for our organization,' said Victoria Morales, PR and Marketing Manager for Onslow Memorial.
This is something they will now be doing quarterly and they will choose winners in April.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Align Technology Announces Invisalign ® System With Mandibular Advancement Featuring Occlusal Blocks for Class II Skeletal and Dental Correction
MUMBAI, INDIA--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced commercial availability in India of the Invisalign System with mandibular advancement featuring occlusal blocks designed specifically to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth. This innovative solution is Align's first clear aligner product with integrated solid occlusal blocks that is designed to deliver predictable mandibular advancement. Invisalign occlusal blocks provide durability, improve engagement, and enable vertical opening to offer earlier advancement of the mandible in cases like skeletal Class II with deep bite to improve treatment efficiency. The Invisalign System with mandibular advancement featuring occlusal blocks is the latest clinical innovation that expands Align's Class II treatment portfolio for growing patients by offering practitioners a comprehensive solution for treating growing patients with Class II malocclusions caused by mandibular retrusion. Class II malocclusion is one of the most common orthodontic problems, characterized by a discrepancy in jaw alignment where the lower jaw (mandible) is positioned too far back relative to the upper jaw (maxilla) and represents approximately 30-45% of malocclusions globally. This condition can lead to functional, aesthetic, and other challenges for patients if left untreated. The Invisalign System with mandibular advancement featuring occlusal blocks is primarily intended for growing patients in the late mixed or early permanent dentition stages (ages 10-16), who are still experiencing growth. By leveraging the natural growth potential during pre-adolescence and adolescence, the Invisalign System with mandibular advancement featuring occlusal blocks facilitates effective correction of Class II malocclusions, helping to improve occlusal relationships, enhance facial aesthetics, and provide long-term functional benefits, including: Efficient treatment. Minimizes the need for multiple appliances to treat conditions including severe deep bite. Treats Class II malocclusions while simultaneously aligning the teeth in a single, efficient process. Invisalign occlusal blocks are solid with laser welding, which ensures structural rigidity and durability throughout the treatment, to minimize crushing. The solid occlusal blocks allow for vertical opening and enables the Mandibular Advancement (MA) phase to begin sooner for Class ll deep bite cases or Class II div 2 patients who many times would have needed a pre-MA phase. Some crossbite cases may still need pre-MA. Elevated patient comfort, (1) and compliance (2). Made from patented SmartTrack™ material, which is predictable and more comfortable (1). Studies show that patient discomfort with functional appliances affects patient compliance with the prescribed wear time and could lead to unsatisfactory outcomes (2). Predictable tooth movement. Attachments are allowed on the teeth under the blocks to facilitate leveling and other movement or to help prevent unwanted movements (3). By combining SmartTrack™ material, SmartForce™ features, and SmartStage™ technology, it also allows for more predictable tooth movement (1). 'The Invisalign System with mandibular advancement featuring occlusal blocks reflects Align's continued commitment to expanding the capabilities of the Invisalign System, enabling doctors to treat a wider range of malocclusions with precision and efficiency, and helps to continue to advance clear aligners as the standard of care in digital orthodontics,' said Sreelakshmi Kolli, Align Technology executive vice president, chief product and digital officer. 'This latest innovation demonstrates our significant investment in delivering digital orthodontic solutions to growing patients that empower doctors to achieve predictable outcomes while enhancing the patient experience.' 'The Invisalign System with mandibular advancement featuring occlusal blocks represents a breakthrough in Class II treatment with clear aligners by allowing doctors to simultaneously address dental and skeletal discrepancies in a more predictable and efficient manner,' said Dr. Mitra Derakhshan, Align Technology executive vice president, chief clinical officer, global treatment planning and clinical services. 'The integration of occlusal blocks enhances mandibular engagement as well as provides bite opening making this a versatile solution for different Class II malocclusion including deep bite or div 2. The Invisalign System with mandibular advancement featuring occlusal blocks, gives doctors and patients a better option for Class II correction in growing patients while simultaneously straightening their teeth, including more options for feature placement, such as attachments on teeth underneath the blocks (3).' 'Treatment outcomes with the Invisalign System with mandibular advancement featuring occlusal blocks are on par with traditional Clark Twin Blocks,' said an orthodontist practicing in New Zealand who has treated 50 patients to date. 'In addition, the enhanced comfort of the Invisalign occlusal blocks increases predictability-- because comfort leads to patient compliance–and compliance leads to better outcomes.' 'Class II correction in growing patients is smooth sailing with the Invisalign System with mandibular advancement featuring occlusal blocks,' said an orthodontist practicing in Australia. 'The patients instinctively know how to bite, and it works so I don't see any crushed blocks. The fact that we see no crushing issues means patients can keep moving through treatment without any delays or additional appointments.' 'I'm very happy with the new Invisalign System with mandibular advancement featuring occlusal blocks design,' said a Canada-based orthodontist. 'Patients can bite down easily without risk of damaging or distorting the blocks, and the mandibular advanced position is easy to maintain. My young patients have found it very easy to transition to this appliance with minimal discomfort, and compliance has been a breeze." 'The Invisalign System with mandibular advancement featuring occlusal blocks provides the ideal block engagement that helps hold the mandible in the proper position for patients that also have mandibular asymmetry. This allows for more efficient corrections when desired,' said an orthodontist based in Canada. 'Invisalign system with mandibular advancement featuring occlusal blocks remove the need for auxiliary elastics, which removes one more obstacle for patients. In addition, the trays do not require palatal coverage like traditional removable Class ll correctors, and there are no changes in the insertion and removal process of the aligners. My younger patients love the ability to remove the aligners for eating, which is not commonly an option for patients that require fixed Class ll correctors or elastics.' The Invisalign System with mandibular advancement featuring occlusal blocks is now commercially available to Invisalign-trained doctors in Australia, New Zealand, Japan, Hong Kong and India, and is expected to be introduced in additional APAC markets later in 2025. Along with the Invisalign® Palatal Expander System, Invisalign First™ and Invisalign System with mandibular advancement featuring occlusal blocks, this latest innovation supports the commitment to establishing a unique and differentiated portfolio that supports growing patients throughout their continuum of care. For more information about the Invisalign System with mandibular advancement featuring occlusal blocks, or to schedule a training session, please visit or contact your local Align Technology representative. 1. Compared to Invisalign aligners previously made from single-layer (EX30) material. 2. Studies show that patient discomfort with functional appliances affect patient compliance with the prescribed wear time and could lead to unsatisfactory outcomes. 3. In some cases, attachments may be removed on teeth under occlusal blocks due to interferences with other features. Expand About Align Technology, Inc. Align Technology designs and manufactures the Invisalign® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat approximately 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
Business Wire
12 hours ago
- Business Wire
Simulations Plus Invests in Clinical Development Technology Company Nurocor
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) ('Simulations Plus'), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies through digitalization in the clinical development phase. Its solution significantly accelerates the typical clinical trial lifecycle, resulting in a reduction of the overall cost of the clinical development process. The investment was made as part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage technology companies accelerating innovations within the pharmaceutical industry. 'We are pleased to support Nurocor in its mission to help clients leverage technology to bring drugs to market more rapidly,' said Shawn O'Connor, Chief Executive Officer of Simulations Plus. 'Their vision aligns with our own, and we see tremendous potential for clients to deploy our complementary solutions in clinical trial design, protocol development, and site competency and compliance. We believe our investment in Nurocor will deliver considerable and measurable value to clients and ultimately get much-needed treatments to patients faster.' 'We are excited to make this strategic investment through our Corporate Development Initiative,' said Will Frederick, Chief Financial Officer of Simulations Plus. 'This initiative is specifically designed to foster growth for early-stage companies, as well as identify potential partners and acquisition targets that complement our organic growth strategy and expand our total addressable market.' In 2024, the clinical trial technology and services sector—which encompasses digital tools and services—was estimated at $25.7 billion. It is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030, driven by the increasing adoption of digital health technologies and the growing demand for more efficient patient recruitment. 'We are thrilled to have the support of Simulations Plus as we enter our next stage of growth,' said Alex Lazar, Chief Executive Officer of Nurocor. 'The investment is a strong vote of confidence in our team and technology, and we look forward to partnering with them to help clients realize efficiencies through the optimization and automation of their clinical trials.' Interested parties can learn more about Simulations Plus' Corporate Development Initiative here. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like 'believe,' 'will', 'can', 'believe', 'expect,' 'anticipate' and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. ###
Yahoo
12 hours ago
- Yahoo
Simulations Plus Invests in Clinical Development Technology Company Nurocor
Investment to accelerate innovations in biopharma development through Corporate Development Initiative RESEARCH TRIANGLE PARK, N.C., July 14, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Founded in 2017, Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies through digitalization in the clinical development phase. Its solution significantly accelerates the typical clinical trial lifecycle, resulting in a reduction of the overall cost of the clinical development process. The investment was made as part of Simulations Plus' Corporate Development Initiative, launched in 2024 to support early-stage technology companies accelerating innovations within the pharmaceutical industry. "We are pleased to support Nurocor in its mission to help clients leverage technology to bring drugs to market more rapidly," said Shawn O'Connor, Chief Executive Officer of Simulations Plus. "Their vision aligns with our own, and we see tremendous potential for clients to deploy our complementary solutions in clinical trial design, protocol development, and site competency and compliance. We believe our investment in Nurocor will deliver considerable and measurable value to clients and ultimately get much-needed treatments to patients faster." "We are excited to make this strategic investment through our Corporate Development Initiative," said Will Frederick, Chief Financial Officer of Simulations Plus. "This initiative is specifically designed to foster growth for early-stage companies, as well as identify potential partners and acquisition targets that complement our organic growth strategy and expand our total addressable market." In 2024, the clinical trial technology and services sector—which encompasses digital tools and services—was estimated at $25.7 billion. It is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030, driven by the increasing adoption of digital health technologies and the growing demand for more efficient patient recruitment. "We are thrilled to have the support of Simulations Plus as we enter our next stage of growth," said Alex Lazar, Chief Executive Officer of Nurocor. "The investment is a strong vote of confidence in our team and technology, and we look forward to partnering with them to help clients realize efficiencies through the optimization and automation of their clinical trials." Interested parties can learn more about Simulations Plus' Corporate Development Initiative here. About Simulations Plus, Inc. With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at Follow us on LinkedIn | X | YouTube. Environmental, Social, and Governance (ESG) We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2024 ESG update. Forward-Looking Statements Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new operational structure, our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission. ### View source version on Contacts Financial Profiles Lisa Fortuna310-622-8251slp@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
